179 related articles for article (PubMed ID: 18563364)
1. Investigation of the relationship between in vitro and in vivo release behaviors of acamprosate from enteric-coated tablets.
Rhee YS; Park S; Lee TW; Park CW; Nam TY; Oh TO; Jeon JW; Lee DS; Park ES
Arch Pharm Res; 2008 Jun; 31(6):798-804. PubMed ID: 18563364
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of acamprosate calcium in healthy Chinese subjects after oral administration of three dosage levels.
Xu F; Qing Y; Shang B; Liang M; Zou Y; Xu G
Arzneimittelforschung; 2009; 59(12):631-4. PubMed ID: 20108648
[TBL] [Abstract][Full Text] [Related]
3. Formulation and in vitro and in vivo availability of diclofenac sodium enteric-coated beads.
Hosny EA; el-Mahrouk GM; Gouda MW
Drug Dev Ind Pharm; 1998 Jul; 24(7):661-6. PubMed ID: 9876511
[TBL] [Abstract][Full Text] [Related]
4. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
Kambayashi A; Blume H; Dressman J
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
[TBL] [Abstract][Full Text] [Related]
5. Analysis of acamprosate in beagle dog plasma by LC-MS-MS.
Rhee YS; Park JH; Park S; Park CW; Ha JM; Jeong KW; Lee DS; Park ES
Arch Pharm Res; 2008 Aug; 31(8):1035-9. PubMed ID: 18787794
[TBL] [Abstract][Full Text] [Related]
6. Considerations in the development of an in vitro dissolution condition for lacidipine tablets: in vivo pharmacokinetic evaluation.
Sun M; Sun J; He S; Wang Y; Sun Y; Liu X; He Z
Drug Dev Ind Pharm; 2012 Sep; 38(9):1099-106. PubMed ID: 22188158
[TBL] [Abstract][Full Text] [Related]
7. Kinetic study of acamprosate absorption in rat small intestine.
Más-Serrano P; Granero L; Martín-Algarra RV; Guerri C; Polache A
Alcohol Alcohol; 2000; 35(4):324-30. PubMed ID: 10905995
[TBL] [Abstract][Full Text] [Related]
8. Design and evaluation of enteric-coated tablets for rifampicin and isoniazid combinations.
Wang Y; Liu H; Liu K; Sun J; He Z
Pharm Dev Technol; 2013; 18(2):401-6. PubMed ID: 22339279
[TBL] [Abstract][Full Text] [Related]
9. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
[TBL] [Abstract][Full Text] [Related]
10. A comparative in vitro assessment of the drug release performance of pH-responsive polymers for ileo-colonic delivery.
Ibekwe VC; Fadda HM; Parsons GE; Basit AW
Int J Pharm; 2006 Feb; 308(1-2):52-60. PubMed ID: 16356670
[TBL] [Abstract][Full Text] [Related]
11. Evidence of a flip-flop phenomenon in acamprosate pharmacokinetics: an in vivo study in rats.
Zornoza T; Cano-Cebrián MJ; Hipólito L; Granero L; Polache A
Biopharm Drug Dispos; 2006 Oct; 27(7):305-11. PubMed ID: 16799924
[TBL] [Abstract][Full Text] [Related]
12. A microdialysis study of extracellular levels of acamprosate and naltrexone in the rat brain following acute and repeated administration.
Burattini C; McGeehan AJ; Griffin WC; Gass JT; Kinder JR; Janak PH; Olive MF
Addict Biol; 2008 Mar; 13(1):70-9. PubMed ID: 18269381
[TBL] [Abstract][Full Text] [Related]
13. Preparation and in vitro-in vivo evaluation of none gastric resident dipyridamole (DIP) sustained-release pellets with enhanced bioavailability.
Xu L; Luo Y; Feng J; Xu M; Tao X; He H; Tang X
Int J Pharm; 2012 Jan; 422(1-2):9-16. PubMed ID: 22001837
[TBL] [Abstract][Full Text] [Related]
14. In vitro dissolution methodology, mini-Gastrointestinal Simulator (mGIS), predicts better in vivo dissolution of a weak base drug, dasatinib.
Tsume Y; Takeuchi S; Matsui K; Amidon GE; Amidon GL
Eur J Pharm Sci; 2015 Aug; 76():203-12. PubMed ID: 25978875
[TBL] [Abstract][Full Text] [Related]
15. Comparative in vitro dissolution and in vivo bioequivalence of two diclofenac enteric coated formulations.
Basmenji S; Valizadeh H; Zakeri-Milani P
Arzneimittelforschung; 2011; 61(10):566-70. PubMed ID: 22164964
[TBL] [Abstract][Full Text] [Related]
16. Clinical pharmacokinetics of acamprosate.
Saivin S; Hulot T; Chabac S; Potgieter A; Durbin P; Houin G
Clin Pharmacokinet; 1998 Nov; 35(5):331-45. PubMed ID: 9839087
[TBL] [Abstract][Full Text] [Related]
17. Effect of decrease in both postprandial blood glucose (PBG) and fasting blood glucose (FBG) levels in normal beagle dogs with nateglinide enteric coated granules and immediate release tablets.
Makino C; Ninomiya N; Sakai H; Orita H; Okano A; Yabuki A
Chem Pharm Bull (Tokyo); 2006 Apr; 54(4):409-14. PubMed ID: 16595936
[TBL] [Abstract][Full Text] [Related]
18. Per-oral controlled release dosage form of theophylline using soybean protein.
Machida Y; Tokumura T; Nagai T
Drug Des Deliv; 1987 Feb; 1(3):187-92. PubMed ID: 3509332
[TBL] [Abstract][Full Text] [Related]
19. Encapsulation of poorly soluble basic drugs into enteric microparticles: a novel approach to enhance their oral bioavailability.
Alhnan MA; Murdan S; Basit AW
Int J Pharm; 2011 Sep; 416(1):55-60. PubMed ID: 21679756
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo evaluation of tegaserod maleate pH-dependent tablets.
Zhang SQ; Thumma S; Chen GH; Deng WB; Repka MA; Li SM
Eur J Pharm Biopharm; 2008 May; 69(1):247-54. PubMed ID: 18037278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
